FindTrial
Sign In

FOY-305-03:FOY-305 TQT study(COVID-19)

FOY-305-03:Thorough QT study of FOY-305 in healthy adult subjects(COVID-19)

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2071200109
Enrollment
39
Registered
2021-03-08
Start date
2021-04-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Single administration of FOY-305, pracebo and moxifloxacin

Sponsors

Osawa Masahiro
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Japanese healthy adult male, >=18 and =18.5 and <25.0 of BMI

Exclusion criteria

Exclusion criteria: Medical history of severe disease, severe allergy for foods and drugs, QTcF>=450ms at SCR

Design outcomes

Primary

MeasureTime frame
Prolongation of QT/QTc interval—

Contacts

Public ContactMedical Center

Ono Pharmaceutical Co.,LTD

clinical_trial@ono.co.jp+81-120-626-190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026